Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study

  • Fisher G
  • Wolin E
  • Kunz P
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: In ELECT, LAN significantly reduced the need for short-acting octreotide rescue medication for symptomatic control of CS in NET patients vs placebo (PBO) in the 16-wk double-blind (DB) phase (primary result). Here we compare patient-reported symptoms in the DB vs 32-wk initial open-label phase (IOL). Methods: Adults with histopathologically confirmed NET and history of CS with/without prior somatostatin analog (SSA) use were randomized to DB LAN 120 mg or PBO every 4 wks for 16 wks followed by a 32-wk IOL on LAN. Patients recorded daily the frequency and severity of diarrhea and/or flushing by Interactive Voice (Web) Response System for 1 month pre-randomization through IOL.Mean composite symptom scores (frequency x severity) in DB vs IOL were analyzed posthoc. Analysis of covariance models (ANCOVA) were used for these analyses with baseline symptoms, prior SSA, and country as factors. Urinary 5-hydroxyindoleacetic acid (u5HIAA) values were log transformed. Results: Of 115 randomized (n = 59 LAN, n = 56 PBO), 56 LAN- and 45 PBO-treated patients, switched to LAN, were available for IOL analysis. Among patients initially on LAN, composite diarrhea scores improved significantly from DB to IOL (mean difference 0.7, 95% CI: 0.22, 1.20; p = 0.005) and were not significantly different for flushing (mean difference -0.2, 95% CI: -1.25, 0.80) or diarrhea and flushing (mean difference 0.5, 95% CI: -0.69, 1.67). As expected, the mean difference in composite scores for diarrhea (1.1, 95% CI: 0.49, 1.65), flushing (1.1, 95% CI: 0.19, 1.93), and diarrhea / flushing (2.1, 95% CI: 0.91, 3.35) reflected significant improvement from DB to IOL for patients initially on PBO (P-values <0.05). Mean (95% CI) differences in u5HIAA between DB wk 12 and IOL wk 48 were -14.75 mumol/d (-27.02, 56.51) for LAN (DB) - LAN (IOL) and 73.96 mumol/d (-11.77, 159.7) for PBO (DB) - LAN (IOL). Frequency of treatment-emergent adverse events (AEs) during IOL by DB group (LAN, PBO) was 69.6% vs 71.1%. The AE profile during IOL was similar to DB. Conclusions: Improved control of diarrhea and flushing in CS patients during initial 16 wks of LAN was sustained through wk 48 of this phase 3 study.

Cite

CITATION STYLE

APA

Fisher, G. A., Wolin, E., Kunz, P. L., Liyanage, N., Mirakhur, B., Lowenthal, S. P., … Vinik, A. (2016). Longer term efficacy of lanreotide autogel/depot (LAN) for symptomatic treatment of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT open label study. Annals of Oncology, 27, vi144. https://doi.org/10.1093/annonc/mdw369.25

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free